The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Synchronous oligometastases in lung cancer
Alan D. L. Sihoe, MBBChir, FRCSEd, FCSHK, FHKAM, The University of Hong Kong, Pokfulam, Hong Kong, talks on synchronous oligometastases in lung cancer. Although stage IV lung cancer is usually incurable, accumulating evidence has demonstrated a subgroup of patients with oligometastatic disease can achieve long-term survival if treated aggressively, particularly synchronous oligometastases. At the time of diagnosis, patients with stage IV synchronous oligometastatic lung cancer have a limited number of metastases that has spread to up to 2 organs. The site of metastasis is an important factor in determining treatment benefit, whereby patients with limited brain metastases tend to have superior outcomes. This interview took place during the virtual European Lung Cancer Congress 2022.
